MAPT and Alzheimer disease: DA was tested as an inhibitor at two tau concentrations using AD brain homogenate as a seed with minimal dilution (high tau load), which is the typical assay condition, or AD brain homogenate diluted 10-fold as a proxy to simulate early disease states with low tau fibril loads.